Digestive Disease Week (DDW 2013)

May 18-21, 2013, Orlando

DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?

Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.

alt

Read more:

DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy

People previously treated with interferon-based therapy can achieve good results when retreated with boceprevir (Victrelis) triple therapy, according to final results from the PROVIDE study presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando. Prior relapsers had the best response, but even 41% of prior null responders achieved a cure.

alt

Read more:

DDW 2013: Drug Interactions May Compromise Response to Boceprevir and Telaprevir

Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C, according to study findings presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.

alt

Read more:

DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus

The newer antivirals tenofovir (Viread) and entecavir (Baraclude) inhibit hepatitis B virus (HBV) replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.

alt

Read more:

DDW 2013: Interferon-free Simeprevir + Sofosbuvir Suppresses Hepatitis C with or without Ribavirin

An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment cure for most prior null responders with genotype 1 hepatitis C in the COSMOS trial, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.

alt

Read more: